Skip to main content

Advertisement

SpringerLink
Log in

Cardiometabolic risk management in type 2 diabetes and obesity

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Type 2 diabetes has become an epidemic in the United States, mainly due to an increase in obesity and sedentary lifestyle. Diabetes is considered a cardiovascular risk equivalent, and cardiovascular death remains the most common cause of death in this population. The cardiovascular complications of diabetes, beginning as early as 10 years before the development of frank hyperglycemia, are strongly linked to the development of insulin resistance and the ensuing metabolic disarray often referred to as the metabolic syndrome. To provide proper therapy for cardiovascular prevention, the down-stream effects of insulin resistance must be understood. The most important aspect of treating patients with the metabolic syndrome is the realization that treatment must begin before the development of frank hyperglycemia, particularly if cardiovascular events are to be avoided. Thus, in addition to managing the hyperglycemia that develops with the onset of diabetes, insulin resistance, dyslipidemia, and hypertension must also be properly addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Engelgau MM, Geiss LS, Saaddine JB, et al.: The evolving diabetes burden in the United States. Ann Intern Med 2004, 140:945–950.

    PubMed  Google Scholar 

  2. Bonow RO, Gheorghiade M: The diabetes epidemic: a national and global crisis. Am J Med 2004, 116(Suppl 5A):2S–10S.

    Article  PubMed  Google Scholar 

  3. Kramer D, Raji A, Plutzky J: Prediabetes mellitus and its links to atherosclerosis. Curr Diab Rep 2003, 3:11–18.

    Article  PubMed  Google Scholar 

  4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.

  5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.

  6. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  7. Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America. Edited by National Diabetes Data Group. Washington, D.C.: National Institutes of Health, NIDDK, NIH publication no. 95-1468; 1995:429–448.

    Google Scholar 

  8. Haffner SM, Stern NP, Hazuda HP: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893–2898.

    Article  PubMed  CAS  Google Scholar 

  9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.

  10. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.

    Article  PubMed  Google Scholar 

  11. Fontbonne AM, Eschwege EM: Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991, 14:461–469.

    Article  PubMed  CAS  Google Scholar 

  12. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  13. Malmberg K, Norhammar A, Wedel H, et al.: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999, 99:2626–2632.

    PubMed  CAS  Google Scholar 

  14. Ceriello A: Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 2004, 147:803–807.

    Article  PubMed  CAS  Google Scholar 

  15. Singh AT, Rainwater DL, Haffner SM, et al.: Effect of diabetes on lipoprotein size. Arterioscler Thromb Vasc Biol 1995, 15:1805–1811.

    PubMed  CAS  Google Scholar 

  16. Siegel RD, Cupples A, Schaefer EJ, et al.: Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metab Clin Exp 1996, 45:1267–1272.

    PubMed  CAS  Google Scholar 

  17. Reaven GM, Chen YD, Jeppesen J, et al.: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993, 92:141–146.

    Article  PubMed  CAS  Google Scholar 

  18. Lehto S, Ronnemaa T, Haffner SM, et al.: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997, 46:1354–1359.

    Article  PubMed  CAS  Google Scholar 

  19. Rosenson RS: Assessing risk across the spectrum of patients with the metabolic syndrome. Am J Cardiol 2005, 96(4A):8E–10E.

    Article  PubMed  Google Scholar 

  20. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense, low-density lipoprotein particles as a predictor of the risk of ischemia heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69–75.

    PubMed  CAS  Google Scholar 

  21. Miller BD, Alderman EL, Haskell WL, et al.: Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996, 94:2146–2153.

    PubMed  CAS  Google Scholar 

  22. Adler AI, Stratton IM, Neil HA, et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412–419.

    Article  PubMed  CAS  Google Scholar 

  23. Kannel WB, Wilson PW, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991, 121(4 Pt 2):1268–1273.

    Article  PubMed  CAS  Google Scholar 

  24. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10K–15K.

    Article  PubMed  CAS  Google Scholar 

  25. Pickup JC: Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813–823.

    Article  PubMed  Google Scholar 

  26. Lee YH, Pratley RE: The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005, 5:70–75.

    Article  PubMed  CAS  Google Scholar 

  27. Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004, 30:13–19.

    Article  PubMed  CAS  Google Scholar 

  28. Greenfield JR, Campbell LV: Relationship between inflammation, insulin resistance and type 2 diabetes: ‘cause or effect’? Curr Diabetes Rev 2006, 2:195–211.

    Article  PubMed  CAS  Google Scholar 

  29. Grant PJ: Diabetes mellitus as a prothrombotic condition. J Intern Med 2007, 262:157–172.

    Article  PubMed  CAS  Google Scholar 

  30. Caballero AE, Arora S, Saouaf R, et al.: Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999, 48:1856–1862.

    Article  PubMed  CAS  Google Scholar 

  31. Fein FS, Sonneblick EH: Diabetic cardiomyopathy. Prog Cardiovasc Dis 1985, 27:255–270.

    Article  PubMed  CAS  Google Scholar 

  32. Yokoyama I, Yonekura K, Ohtake T, et al.: Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. J Nucl Med 2000, 41:978–985.

    PubMed  CAS  Google Scholar 

  33. Gonzalez MA, Selwyn AP: Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003, 115(Suppl 8A):99S–106S.

    Article  PubMed  CAS  Google Scholar 

  34. Makimattila S, Liu ML, Vakkilainen J, et al.: Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999, 22:973–981.

    Article  PubMed  CAS  Google Scholar 

  35. Ceriello A, Taboga C, Tonutti L, et al.: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 2002, 106:1211–1218.

    Article  PubMed  Google Scholar 

  36. Rim SJ, Leong-Poi H, Lindner JR, et al.: Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation 2001, 104:2704–2709.

    Article  PubMed  CAS  Google Scholar 

  37. Rosenson RS, Lowe GD: Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998, 140:271–280.

    Article  PubMed  CAS  Google Scholar 

  38. Kohno M, Murakawa K, Yasunari K, et al.: Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metab Clin Exp 1997, 46:287–291.

    PubMed  CAS  Google Scholar 

  39. Scognamiglio R, Negut C, Vigli de Kreutzenberg S, et al.: Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005, 112:179–184.

    Article  PubMed  Google Scholar 

  40. Kawano H, Motoyama T, Hirashima O, et al.: Hyperglycemia rapidly suppresses flow-mediated endothelium dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 43:146–154.

    Article  Google Scholar 

  41. Scognamiglio R, Negut C, Vigli de Kreutzenberg S, et al.: Effects of different insulin regimens on postprandial perfusion defects on type 2 diabetic patients. Diabetes Care 2006, 29:95–100.

    Article  PubMed  CAS  Google Scholar 

  42. Bolad I, Delafontaine P: Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol 2005, 20:270–274.

    Article  PubMed  Google Scholar 

  43. Svensson AM, McGuire DK, Abrahamsson P, et al.: Association between hyper-and hypoglycemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005, 26:1255–1261.

    Article  PubMed  Google Scholar 

  44. Meier JJ, Deifuss S, Klamann A, et al.: Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005, 28:2551–2553.

    Article  PubMed  Google Scholar 

  45. Chaudhuri A, Janicke D, Wilson MF, et al.: Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004, 109:849–854.

    Article  PubMed  CAS  Google Scholar 

  46. Malmberg K, Ryden L, Wedel H, et al.: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650–661.

    Article  PubMed  CAS  Google Scholar 

  47. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.

  48. Effect of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545–2559.

  49. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560–2572.

  50. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005–2016.

    Article  PubMed  Google Scholar 

  51. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513–2519.

    PubMed  CAS  Google Scholar 

  52. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  PubMed  CAS  Google Scholar 

  53. Schaefer EJ, McNamara JR, Shah PK, et al.: Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 2002, 25:989–994.

    Article  PubMed  CAS  Google Scholar 

  54. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.

    Article  PubMed  CAS  Google Scholar 

  55. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  56. Gustafsson I, Torp-Pedersen C, Kober L, et al.: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. J Am Coll Cardiol 1999, 34:83–89.

    Article  PubMed  CAS  Google Scholar 

  57. Telmisartan, ramipril, or both in patients at high risk for vascular events. The ONTARGET Investigators [no authors listed]. N Engl J Med 2008, 358:1547–1559.

  58. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  59. Gaede P, Vedel P, Larsen N, et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383–393.

    Article  PubMed  Google Scholar 

  60. Krolewski KS, Warren JH, Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90:56S–61S.

    Article  PubMed  CAS  Google Scholar 

  61. Daly C, Clemens F, Lopez Sendon JL, et al.: Gender differences in the management and clinical outcomes of stable angina. Circulation 2006, 113:490–498.

    Article  PubMed  Google Scholar 

  62. Shaw LJ, Merz CNB, Pepine CJ, et al.: Insights from the NHLBI-sponsored women’s ischemia syndrome evaluation (WISE) study: part 1: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006, 47:4S–20S.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, University of Virginia, 1215 Lane Street, Hospital Expansion Building C, Box 800158, Charlottesville, VA, 22908, USA

    Angela M. Taylor

Authors
  1. Angela M. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela M. Taylor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Taylor, A.M. Cardiometabolic risk management in type 2 diabetes and obesity. Curr Diab Rep 8, 345–352 (2008). https://doi.org/10.1007/s11892-008-0061-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-008-0061-7

Keywords

Search

Navigation